×

AngioDynamics Announces the Approval of the Celerity PICC Tip Confirmation System With Navigation in Canada

ALBANY, N.Y., Feb. 08, 2016 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Celerity PICC Tip Confirmation System with Navigation has been approved by Health Canada for the positioning of Peripherally Inserted Central Catheters (PICCs) in adult patients.

Celerity with Navigation offers enhanced features to the previous version of the tip location system, including real-time catheter tracking, allowing clinicians the ability to see the location of the PICC tip at all times, providing for an improved clinician experience.

“This is an important milestone as it is the first clearance for Celerity with Navigation,” said Joseph M. DeVivo, President and CEO of AngioDynamics. “We have a very strong PICC business in Canada and we are pleased to bring this technology to PICC teams throughout the country. Also, we filed for US FDA 510k clearance in November, and are hoping to receive that approval before the end of our fiscal year.”

“The approval of Celerity with Navigation by Health Canada is a tremendous opportunity for the AngioDynamics sales team, our customers and patients,” said Chuck Greiner, Senior Vice President of AngioDynamics' Global Vascular Access Franchise. “This technology allows more clinicians and patients to experience the clinical benefits of BioFlo. Many of our customers are dependent upon Navigation for PICC placement, but have a desire to use BioFlo. The launch of Celerity with Navigation will allow those customers to access the anti-thrombogenic benefits that BioFlo offers along with the increased ease-of-use that the technology offers. We are now better positioned than ever to compete in the global PICC market.”

Health Canada’s approval marks the first clearance for the extended Celerity PICC Tip Confirmation System with Navigation technology. AngioDynamics anticipates having Celerity with Navigation commercially available during the company’s fiscal fourth quarter.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo, and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Celerity is a trademark and/or registered trademark of Medical Components, Inc.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2015 and its quarterly report on Form 10-Q for the fiscal period ended August 31, 2015 and November 30, 2015. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

Company Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com Investor Relations Contacts: EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 dsherk@evcgroup.com cdailey@evcgroup.com Media Contact: EVC Group, Inc. Dave Schemelia (646) 201-5431 dave@evcgroup.com

Source:AngioDynamics